Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients
NCT02226757
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
16
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
HER2-expression
EGFR-mutation
Interventions
DRUG:
Paclitaxel-trastzumab
Sponsor
Amsterdam UMC, location VUmc